The optimal dosing of gemtuzumab ozagamicin: where to go from here?

Haematologica. 2016 Jun;101(6):653-4. doi: 10.3324/haematol.2016.145763. Epub 2016 May 31.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Aged
  • Aged, 80 and over
  • Aminoglycosides / adverse effects
  • Aminoglycosides / therapeutic use*
  • Antibodies, Monoclonal, Humanized / adverse effects
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Female
  • Gemtuzumab
  • Humans
  • Leukemia, Myeloid, Acute / drug therapy*
  • Male
  • Middle Aged
  • Myelodysplastic Syndromes / drug therapy*

Substances

  • Aminoglycosides
  • Antibodies, Monoclonal, Humanized
  • Gemtuzumab